Analysis of Biomarkers From Patients With Chorioretinal Diseases

NCT ID: NCT02026843

Last Updated: 2025-03-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-04-30

Study Completion Date

2031-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was conducted to investigate the levels of ocular biomarkers from the patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective, case-control study included 50 patients(50eyes) with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. and 50 patient with nondiabetic retinopathy or cataract. Ocular fluids and blood samples were taken before injection of anti-vascular endothelial growth factor agent or pars plana vitrectomy for other retinal disease. Ocular biomarkers were analyzed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Retinopathy Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chorioretinal diseases

chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.

Chorioretinal diseases

Intervention Type DRUG

chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration

Control

control patients with surgeries include pars plana vitrectomy of macular hole, epiretinal membrane, cataract surgery.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chorioretinal diseases

chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age over 20 years
* patients requiring ophthalmologic treatments for different degrees of decreasing of visual acuity.
* patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.
* control patients asking cataract surgery or vitrectomy for posterior segment nonproliferative disorders.

Exclusion Criteria

* under the age of 20 years
* patients that received any anti-vascular endothelial growth factor agent for proliferative disease before taking sample of aqueous humor
* patients that did not signed the informed consent of the trial
* patients with intraocular inflammations or infections that requiring any pharmaceutical agent
* patients with recent ocular trauma
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kyungpook National University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dong Ho Park

Department of Opthalmology, School of medicine, Kyungpook National University

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dong Ho Park, M.D

Role: PRINCIPAL_INVESTIGATOR

Kyungpook National University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dong Ho Park

Daegu, Kyungsangpookdo, South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dong Ho Park, M.D.

Role: CONTACT

82-53-420-5813

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dong Ho Park, M.D

Role: primary

82-53-420-5813

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KNUH2013-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.